Research programme: cancer immunotherapeutics - ImmuNext/Janssen
Latest Information Update: 16 Jul 2016
At a glance
- Originator ImmuNext
- Developer ImmuNext; Janssen Biotech
- Mechanism of Action Immunomodulators; VISTA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 05 Sep 2012 Early research in Cancer in USA (unspecified route)